MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
| Price | $1.36 |
|---|---|
| Market cap | $82.69M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | AMEX |
| 52-week range | 0.87-3.19 |
| Beta | 0.26 |
Explore MAIA's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.